英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
mucilagineux查看　mucilagineux　在百度字典中的解释百度英翻中〔查看〕
mucilagineux查看　mucilagineux　在Google字典中的解释Google英翻中〔查看〕
mucilagineux查看　mucilagineux　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • IMBRUVICA® (ibrutinib) | Official Patient Website
    ‡ IMBRUVICA® By Your Side patient support program is not intended to provide medical advice, replace prescribed treatment plans, or provide treatment or case management services Patients are advised to talk to their healthcare provider and treatment team about any medical decisions and concerns they may have
  • Ibrutinib in Patients with Relapsed or Refractory Diffuse . . .
    Based on gene profiling, DLBCL can be further classified as activated B-cell-like lymphoma (ABC), germinal center B-cell-like lymphoma (GCB) and primary mediastinal B-cell lymphoma Most patients of DLBCL achieve complete remission (CR) after treatment with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), which is
  • Ibrutinib improves diffuse large B-cell lymphoma survival
    NCI researchers have found that adding the targeted therapy ibrutinib (Imbruvica) to standard chemotherapy can improve how long some younger people with a specific form of diffuse large B-cell lymphoma live The new findings come from a new analysis of a previously conducted phase 3 clinical trial called Phoenix
  • Imbruvica (Ibrutinib) | Lymphoma News Today
    A total of 56 patients with various types of B-cell NHL were enrolled in the study The results showed that Imbruvica was well-tolerated across various types of B-cell NHL The FDA approved Imbruvica in 2013 for the treatment of patients with MCL based on the results of an open-label Phase 2 trial (NCT01236391) During the trial, 111 patients
  • Ibrutinib improves survival for younger people with diffuse . . .
    “This new analysis provides a compelling rationale for doctors to consider adding ibrutinib to standard chemotherapy for the initial treatment of younger patients with non-GCB DLBCL,” said Wyndham H Wilson, M D , Ph D , senior investigator in the Lymphoid Malignancies Branch and a co-author of the study DLBCL is the most common type of
  • IMBRUVICA® (ibrutinib) receives positive CHMP opinion for the . . .
    BEERSE, BELGIUM (20 June 2025) – Janssen-Cilag International NV, a Johnson Johnson company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval for an indication extension of IMBRUVICA ® (ibrutinib) in frontline mantle cell lymphoma (MCL)
  • Efficacy and safety of ibrutinib in diffuse large B-cell . . .
    The pooled OR and CR were 64 2 % and 56 9 % in non-germinal center B-cell-like (non-GCB) DLBCL and 68 3 % and 36 0 % in relapsed refractory central nervous system lymphoma (CNSL), respectively The pooled median progression-free and overall survival were 4 54 months and 11 5 months, respectively 70 7 % and 52 6 % patients experienced ≥ grade
  • Official Healthcare Professional Website | IMBRUVICA . . .
    Manage cardiac arrhythmias and cardiac failure appropriately, follow dose modification guidelines, and consider the risks and benefits of continued IMBRUVICA ® treatment Hypertension: Hypertension occurred in 19% of 1,476 patients with B-cell malignancies who received IMBRUVICA ® in clinical trials Grade 3 or greater hypertension occurred
  • Imbruvica - opinion on variation to marketing authorisation
    Imbruvica in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (Imbruvica + R-CHOP) alternating with R-DHAP (or R-DHAOx) without Imbruvica, followed by Imbruvica monotherapy, is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who would be eligible for
  • Imbruvica oral forms: Side effects, dosage, uses, and more
    Imbruvica for diffuse large B-cell lymphoma Imbruvica isn’t currently approved for use in people with diffuse large B-cell lymphoma (DLBCL) However, your doctor may prescribe the drug off
  • CLL and SLL Treatment | IMBRUVICA® (ibrutinib)
    The most common side effects of IMBRUVICA® in adults with B-cell malignancies (CLL SLL and WM) include low platelet count; diarrhea; tiredness; muscle, bone, and joint pain; low white blood cell count; rash; low red blood cell count (anemia); bruising; and nausea
  • U. S. FDA Approves IMBRUVICA® (ibrutinib) as First Treatment . . .
    Marginal zone lymphoma (MZL) is a slow-growing B-cell lymphoma arising from white blood cells (lymphocytes) at the edges of lymphoid tissue 3 MZL accounts for approximately 8% of all cases of non-Hodgkin's lymphoma in adults, and the median age of diagnosis is 65 years old 3,4 There are three sub-types of MZL: mucosa-associated lymphoid





中文字典-英文字典  2005-2009